NCT06952556 Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO/DFO/TTO
| NCT ID | NCT06952556 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | NYU Langone Health |
| Condition | Analgesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-04-28 |
| Primary Completion | 2027-04-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2025-04-28 with a primary completion date of 2027-04-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A randomized, single-blind, single-center study measuring the effects of adductor canal block combined with IPACK infiltration compared to adductor canal block alone on post-operative pain and opioid consumption in patients undergoing high tibial osteotomy (HTO)/distal femoral osteotomy (DFO)/tibial tubercle osteotomy (TTO).
Eligibility Criteria
Inclusion Criteria: * Patients between 18 and 75 years of age * Patients undergoing HTO/DFO/TTO. * American Society of Anesthesiologists (ASA) I or II Exclusion Criteria: * Patients younger than 18 and older than 75. * Patients with multi-ligament injury * Patients undergoing concomitant cartilage procedure or ACLR. * Patients with a history of chronic pain that have used opioids for pain management for 3 months or longer. * Patients who are allergic to oxycodone; * Patients with diagnosed or self-reported cognitive dysfunction; * Patients with a history of neurologic disorder that can interfere with pain sensation; * Patients with a history of drug or recorded alcohol abuse; * Patients who are unable to understand or follow instructions; * Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease; * Patients with an allergy or contraindication to any of the medications used in the study, or patients with a contraindication to any study procedures; * Patients with a BMI over 45; * Any patient that the investigators feel cannot comply with all study related procedures; * Any pregnant patient; assessed via urine pregnancy test in the preoperative area as part of standard preoperative surgical protocol;
Contact & Investigator
Laith Jazrawi, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06952556 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06952556 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06952556 currently recruiting?
Yes, NCT06952556 is actively recruiting participants. Contact the research team at Laith.jazrawi@nyulangone.org for enrollment information.
Where is the NCT06952556 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06952556 clinical trial?
NCT06952556 is sponsored by NYU Langone Health. The principal investigator is Laith Jazrawi, MD at NYU Langone Health. The trial plans to enroll 100 participants.